Amgen Deal Blocks Celltrion’s Bone-Drug Biosimilars Until June

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing in New Jersey federal court.

Celltrion agreed its biosimilars infringe 29 patents covering denosumab—the active ingredient in both biologics—along with methods of manufacturing it and products containing it, according to a consent judgment and injunction docketed Jan. 24 in the US District Court for the District of New Jersey.

• The deal blocks Celltrion from selling its biosimilars in the US or from importing them into the country “except as ...